HALO Halozyme Therapeutics, Inc.

NASDAQ
$106.94

Halozyme Therapeutics, Inc. (HALO) SEC Filings

Everything HALO has filed with the SEC, newest first. An 8-K shows what it was about where we have classified it — an earnings release and a change of chief executive are both 8-Ks, and the form number alone doesn't separate them.

80 filings
Date Form Filing
8-K View filing
8-K Capital Raise · Debt · Dilution · Material Agreement View filing
8-K Capital Raise · Other Event View filing
4 View filing
144 View filing
8-K Capital Raise · Other Event View filing
4 View filing
4 View filing
4 View filing
8-K Executive Change View filing
4 View filing
10-Q View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
10-Q View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
10-K View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
10-Q View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
10-Q View filing
10-Q View filing
10-K View filing
10-Q View filing
10-Q View filing
10-Q View filing
10-K View filing
10-Q View filing
10-Q View filing
10-Q View filing
10-K View filing
10-Q View filing
10-Q View filing
10-Q View filing
10-K View filing
10-Q View filing

Filings are sourced from EDGAR and open on the SEC's own site. Classification of 8-K events is ours and is not part of the filing.